Generic Lamictal Buyers Defend Class Cert. At 3rd Circ.

By Matthew Santoni ( July 29, 2019, 10:01 PM EDT) -- Drug wholesalers have urged the Third Circuit to keep their class certification intact in a case alleging GlaxoSmithKline and Teva Pharmaceuticals' deal to delay generic versions of Lamictal harmed buyers of the mood stabilizer, citing the drugmakers' admissions that prices would have been lower had more generics been available....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!